U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285122) titled 'Phase 1 Dose-escalation Study of Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers' on Dec. 03.
Brief Summary: This is a 3-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled RB042.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy
Healthy Smoker
Intervention:
DRUG: RB042
A single or multiple doses of RB042 will be administered via a nebuliser.
DRUG: Placebo inhalation solution
A single or multiple doses of placebo will be administered via a nebuliser.
Recruitment Status: NO...